Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01294319 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men
A Phase 2 study of ACTH and Cortisol Resistance, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT01294319 is a Phase 2 study of ACTH and Cortisol Resistance that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 51 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01294319, a Phase 2 study of ACTH and Cortisol Resistance, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
This study proposes to examine multiple aspects of the hypothalamic-pituitary-adrenal axis in younger endurance trained and sedentary men, and in older sedentary men.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dexamethasone
- DRUG Spironolactone
- DRUG Mifepristone
- DRUG Combined
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2011-01-24 |
| Est. Completion | 2016-08-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01294319
The ClinicalTrials.gov registry entry for NCT01294319 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with ACTH appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01294319 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01294319 about?
NCT01294319 is a clinical study titled "Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men". This study proposes to examine multiple aspects of the hypothalamic-pituitary-adrenal axis in younger endurance trained and sedentary men, and in older sedentary men.
What is the current status of trial NCT01294319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2011-01-24. Estimated completion is 2016-08-10.
What conditions does trial NCT01294319 study?
This clinical trial studies the following conditions: ACTH, Cortisol Resistance, Negative Feedback, Mineralcorticoid, Glucocorticoid.
What interventions are being tested in trial NCT01294319?
The interventions under investigation include: Placebo (DRUG), Dexamethasone (DRUG), Spironolactone (DRUG), Mifepristone (DRUG), Combined (DRUG).
Who is sponsoring clinical trial NCT01294319?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01294319 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ACTH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.